Advertisement
Advertisement
TOPIC

Biomedicine: Geopolitics

Related Topics:
Biomedicine: Geopolitics
Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.
AstraZeneca’s booth at the China International Supply Chain Expo in Beijing, July 17, 2025. Photo: EPA
Made in China 2025

Global drug giants double down on China amid push for self-reliant supply chains

Multinationals are building self-reliant supply chains in China to insulate local markets from potential trade disruptions, say analysts.

China’s private sector

US reshoring drive casts shadow over China’s contract drug makers, analyst says

China’s private sector

Eli Lilly boosts China footprint with US$3 billion plan to expand supply chain

China trade

China supply chain expo set to welcome more US firms, launch AI section

Amid trade tensions, China Council for the Promotion of International Trade describes business communities as a ‘bridge’ for exchanges.

videocam
Robots at the Nvidia booth at the third China International Supply Chain Expo in Beijing in July 2025. Photo: Xinhua
Made in China 2025

Capital injection: China backs AI drug makers in self-reliance drive

A wave of government-linked investment is boosting Chinese AI drug makers, underscoring Beijing’s drive to build its own biotech ecosystem.

Hong Kong stock market

WuXi Biologics earnings jump as ‘follow and win the molecule’ strategy pays off

Chinese contract drug maker forecasts 46.3 per cent profit rise and signals continued growth despite US political scrutiny.

Advertisement
Advertisement
Advertisement
China’s private sector

Biomedicine | China challenges US in new drugs after industry transformation

Drug makers in China are performing cutting-edge research and licensing products to global giants after a 10-year government push supercharged the industry.

China challenges US in new drugs after industry transformation
China economy

Opinion | How a rising China is becoming a provider of global public goods

When China provides the hi-tech, low-cost hardware of development and multilateral banks provide regulatory oversight, the Global South wins.

Biomedicine: Industry Trends

China could approve first AI-designed drug next year, Merck executive says

AI and genetics are creating a ‘seismic shift’ in the pharmaceutical business, experts on Asian Financial Forum panel say.

US-China relations

Opinion | China has Trump 2.0 to thank for emerging stronger in tech and trade

As intense US-China competition becomes the new normal, pressure has strengthened China’s capacity to adapt rather than deter it from its long-term ambitions.

videocam
President Xi Jinping attends a high-level reception to ring in the Lunar New Year at the Great Hall of the People in Beijing, on January 27, 2025. Photo: Xinhua
Biomedicine: Industry Trends

Harbour BioMed stake in US drug developer shows Chinese firms’ growing clout

Latest example of Chinese drug maker acquiring equity in overseas partner shows they are becoming true development partners, analysts say.

Global drug companies no longer view Chinese firms as contract manufacturers, but as development partners, an analyst says. Photo: Shutterstock
Made in China 2025

Exclusive | China challenges US in AI drug race, but rivals still reliant on each other

While US biotech firms increase use of Chinese clinical data, Chinese firms need US counterparts for monetisation, investor and scientist says.

Science

Structural biologist Alexey Amunts launches new research lab in Shenzhen

‘Shenzhen adds another dimension; it is a place where ideas do not remain ideas for long,’ Amunts says of new position.

videocam
8
Made in China 2025

Chinese biotechs strike a record US$136 billion in out-licensing deals in 2025

Chinese drug makers signed 157 out-licensing deals with global pharmaceutical firms last year versus 94 a year earlier.

Last year, China approved 76 innovative drugs, including 47 chemical drugs and 23 biologics. Photo: Shutterstock
Banking & finance

Global firms turn to M&A in EVs and biotech to deepen China investment: KPMG

Survey of multinational corporations finds optimism in life sciences, healthcare and manufacturing, with half forecasting revenue growth.

Healthcare and life sciences are the top growth prospects over the next three to five years, according to multinational corporations. Photo: Xinhua
United States

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.

China’s private sector

BeOne Medicines names R&D chief Wang Lai as president amid global expansion

BeOne generated global revenue of about US$3.8 billion last year, driven by its flagship products Brukinsa and Tevimbra.

Advertisement
Advertisement
Advertisement
Made in China 2025

Chinese biotech Scizeng’s global licensing deal to yield up to US$1.44 billion

Yarrow Bioscience gets exclusive global rights for the GenSci098 therapy to treat thyroid eye disease and Graves’ disease.

A number of Chinese biotech firms have clinched licensing deals with multinational companies this year. Photo: Shutterstock
Science

China overtakes US in medical research in science power shift: top publisher

Country is ‘now global leader in scientific publishing and output’, Fred Fenter, chief executive editor of Swiss-based Frontiers, says.

videocam
30
China-Africa relations

China’s ‘health silk road’ in Africa gets a boost with insulin, pharma projects

Move to manufacture insulin locally is set against forecast of nearly 55 million Type 2 diabetes cases in sub-Saharan Africa by 2045.

videocam
China’s private sector

‘Quantity to quality’: what China’s next 5-year plan means for foreign investors

Beijing has pledged to open up even more to foreign investment. But some officials are becoming more selective about the projects they want.

videocam
Illustration: Brian Wang
Baidu

Baidu-backed drug discovery start-up Biomap challenges Google’s AlphaFold

Biomap expects to double its revenue this year, co-founder and CEO Wei Liu says.

From left to right: HKIC CEO Clara Chan Ka-chai, Financial Secretary Paul Chan Mo-po and Biomap CEO Wei Liu at a signing ceremony in June. Photo: Handout
Biomedicine: Companies

Trump’s tariffs on imported drugs ‘not a big concern’ for China’s pharma firms

Chinese drug makers have ‘minimal sales exposure to the US’, Jefferies analysts say.

US-China relations

Opinion | Why US-China health and drugs cooperation must top Trump-Xi agenda

The years-long impasse harms both nations and the world, and the stakes in global health security could not be higher.

videocam
US-China tech war

Chinese 3D biomolecule imaging start-up aims for IPO in 2027

Shuimu BioSciences is the first Chinese company to develop its own cryo-electron microscopy machine, a vital tool in drug discovery.

Allen Guo Chunlong, co-founder and CEO Shuimu BioSciences. Photo: Handout
Banking & finance

Global investment funds are tiptoeing into Hong Kong, aided by HKIC

“Geopolitics is not going away any time soon, but smart money needs to invest in the future,” the Hong Kong Investment Corporation’s CEO Clara Chan says.

Pedestrians in Tsim Sha Tsui on August 26, 2025. Photo: Jelly Tse
China technology

China’s biotech industry is gaining on the US. Can tariffs hold them back?

Pharmaceutical firms in China have grown fast, but geopolitics and a long head start could keep US-based leaders at industry apex - for now.

videocam
US-China trade war

China, US end Stockholm trade talks, diverge on timing of tariff pause extension

After third round of negotiations, China signals consensus is reached while US team says no agreement until President Trump approves.

videocam
51
Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement